Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

157
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
157
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.1K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

349
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
349
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

341
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
341
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

1.8K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.8K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

154
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
154

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large Language Models Meet Biomedical Knowledge Graphs for Mechanistically Grounded Therapeutic Prioritization.

ArXiv·2026
Same author

DeepER-Med: Advancing Deep Evidence-Based Research in Medicine Through Agentic AI.

ArXiv·2026
Same author

Fangchinoline alleviates hypertensive heart failure via PGC-1α/STAT6/PPARγ activation of mitophagy against ferroptosis.

British journal of pharmacology·2026
Same author

Silencing Triglycerides: The Clinical Impact of Plozasiran and apoC-III Inhibition in Severe Hypertriglyceridemia.

Journal of cardiovascular pharmacology·2026
Same author

Halodule uninervis ethanolic extract reduces inflammation in LPS-stimulated RAW 264.7 macrophages via NF-κB, STAT3, and MAPK modulation.

Scientific reports·2026
Same author

Mechanistic interactions between curcumin and statins: pharmacological convergence and therapeutic implications.

Molecular biology reports·2026

Related Experiment Video

Updated: Dec 10, 2025

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.7K

Repurposing Cilostazol for Raynaud's Phenomenon.

Nehme El-Hachem1, Manal M Fardoun2, Hasan Slika3

  • 1Laboratory of Medical Genetics, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, Beirut, Lebanon.

Current Medicinal Chemistry
|September 4, 2020
PubMed
Summary
This summary is machine-generated.

Raynaud's Phenomenon (RP) involves exaggerated vasoconstriction. Cilostazol, a drug for intermittent claudication, shows potential in improving blood flow for RP patients by enhancing digital perfusion.

Keywords:
Cardiovascular diseaseCold-induced vasoconstrictionRaynaud's phenomenoncilostazoldigital ischemiadrug repurposing

More Related Videos

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.4K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.8K

Related Experiment Videos

Last Updated: Dec 10, 2025

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.7K
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.4K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.8K

Area of Science:

  • Vascular Medicine
  • Pharmacology

Background:

  • Raynaud's Phenomenon (RP) is characterized by exaggerated cold-induced vasoconstriction, leading to compromised digital blood flow and potential tissue damage.
  • Current treatments for RP, including calcium-channel blockers and prostacyclin analogs, primarily manage symptoms rather than offering a cure, with no FDA-approved drugs specifically for RP.

Purpose of the Study:

  • To review the mechanisms by which cilostazol, a phosphodiesterase-III inhibitor, may enhance blood perfusion in patients with Raynaud's Phenomenon.
  • To explore the potential repurposing of cilostazol as a therapeutic agent for RP, leveraging its vasodilating and antiplatelet properties.

Main Methods:

  • Literature review of studies investigating cilostazol's pharmacological actions.
  • Analysis of cilostazol's effects on vascular tone, platelet aggregation, and blood flow, particularly in the context of conditions similar to RP.

Main Results:

  • Cilostazol exhibits antiplatelet and vasodilating properties that could counteract the exaggerated vasoconstriction seen in RP.
  • Its mechanism of action, involving phosphodiesterase-III inhibition, may lead to increased cyclic adenosine monophosphate (cAMP) levels, promoting vasodilation and improved blood flow.

Conclusions:

  • Cilostazol presents a promising therapeutic option for enhancing blood perfusion in Raynaud's Phenomenon patients.
  • Further clinical investigation is warranted to establish the efficacy and safety of cilostazol for treating RP and potentially gaining FDA approval.